Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From ProBioGen AG

Pionyr Maps Tumor Microenvironment, Plans 'Surgical' Strikes

Emerging Company Profile: Pionyr Immunotherapeutics exec who once led early development for Merck's PD-1 inhibitor Keytruda explains the San Francisco start-up's approach to rebalancing the tumor's microenvironment in order to improve outcomes.

StartUps and SMEs ImmunoOncology

Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie

Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.

Deals Business Strategies

Recent Dealmaking (11/2003)

Summarizing the month in European dealmaking.

Recent Dealmaking (10/2003)

Summarizing the month in European dealmaking.

See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • In Vitro Diagnostics
  • Pharmaceuticals
UsernamePublicRestriction

Register